Zavondemstat L-lysine

Overview

Zavondemstat (QC8222; TACH 101) L-lysine is an orally active pan- KDM4 inhibitor, with a IC 50 ≤ 0.08 μM against human KDM4A-D and a Kᵢ of 0.52 μM against human KDM4C. Zavondemstat L-lysine induces cell apoptosis , causes S-phase cell cycle arrest, reduces the population of tumor-initiating cells and inhibits cancer cell proliferation. Zavondemstat L-lysine suppresses tumor growth and induces tumor regression in mouse xenograft models. Zavondemstat L-lysine can be used for the research of various cancers including colorectal cancer , esophageal squamous cell carcinoma and triple-negative breast cancer .

Application

Products | Products > Disease Areas > Cancer | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Epigenetics | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Histone Demethylase

Product Information

• Catalog No.: HY-148807A
• CAS No.: 2908753-10-4
• Molecular Formula: C32H43N5O5
• Molecular Weight: 577.71
• Purity: 99.98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source